Nicholas Investment Partners’s TherapeuticsMD TXMD Stock Holding History

Nicholas Investment Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-18,944	Closed	-$4.61M	–	234
2019 Q1	$4.61M	Buy	+18,944	New	+$5.01M	0.41%	79
2016 Q3	–	Sell	-6,644	Closed	-$2.82M	–	327
2016 Q2	$2.82M	Buy	6,644 +1,706	+35%	+$703K	0.2%	215
2016 Q1	$1.58M	Sell	4,938 -691	-12%	-$236K	0.12%	260
2015 Q4	$2.92M	Sell	5,629 -3,337	-37%	-$1.23M	0.2%	210
2015 Q3	$2.63M	Buy	8,966 +4,114	+85%	+$1.46M	0.19%	213
2015 Q2	$1.91M	Sell	4,852 -1,559	-24%	-$550K	0.12%	267
2015 Q1	$1.94M	Buy	+6,411	New	+$1.57M	0.12%	259
2014 Q4	–	Sell	-1,498	Closed	-$348K	–	318
2014 Q3	$348K	Sell	1,498 -8,993	-86%	-$2.27M	0.02%	294
2014 Q2	$2.32M	Buy	10,491 +199	+2%	+$44.3K	0.14%	223
2014 Q1	$3.25M	Buy	+10,292	New	+$3.28M	0.27%	124

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nicholas Investment Partners's TXMD Position: Q2 2019 in Review

Nicholas Investment Partners sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 18,944 shares — an estimated $4.61M sold.

Nicholas Investment Partners first reported a position in TXMD in Q1 2014 and held it in 10 quarters. The position peaked at $4.61M in Q1 2019. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

Nicholas Investment Partners reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
Nicholas Investment Partners sold 18,944 TherapeuticsMD shares in Q2 2019, an estimated $4.61M.
Nicholas Investment Partners first reported a position in TherapeuticsMD in Q1 2014 and held it in 10 quarters.
Nicholas Investment Partners's TherapeuticsMD position peaked at $4.61M in Q1 2019.
148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Nicholas Investment Partners's 13F filing for Q2 2019, filed 9 Aug 2019.